Subtype
Cervical Neoplasm
CI-CAN-00004801Explore in graph →
Non-malignant573 active trials4 approved drugs14 evidence items
Loading cancer entity…
Subtype
CI-CAN-00004801Explore in graph →
Clinical trials
2,386 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07090174 | CASCADE: Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV | withdrawn | Phase 2 | 0 | University of California, San DiegoOTHER | 2 | Aug 19, 2026 | clinicaltrials |
| NCT07211204 | Comparison Of Cytology And Molecular Screening For Detecting Cervical Reactive Cellular Changes In General Population | withdrawn | N/A | 0 | Timser SAPI de CVINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07226102 | Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer | withdrawn | N/A | 0 | City of Hope Medical CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05850663 | Quality of Life Assessment of Radiotherapy in Recurrent Head and Neck Cancer | withdrawn | N/A | 0 | University of OklahomaOTHER | 0 | Feb 3, 2026 | clinicaltrials |
| NCT02554344 | Effect of Curcumin in Treatment of Squamous Cervical Intraepithelial Neoplasias (CINs) | withdrawn | Early Phase 1 | 0 | Baylor Research InstituteOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06626256 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Dec 24, 2025 | clinicaltrials |
| NCT06866951 | A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial | withdrawn | Phase 2 / Phase 3 | 0 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06393751 | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jun 3, 2025 | clinicaltrials |
| NCT02446652 | Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer | withdrawn | Phase 3 | 0 | National Institute of CancerologíaOTHER_GOV | 1 | May 29, 2025 | clinicaltrials |
| NCT04889495 | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer | withdrawn | — | 0 | PfizerINDUSTRY | 0 | Mar 19, 2025 | clinicaltrials |
| NCT05470309 | Community Outreach-based Study to Increase Cervical Cancer Screening Among Hispanic Women in Cleveland | withdrawn | — | 0 | MetroHealth Medical CenterOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT03677024 | Evaluation of the Efficacy for Sentinel Lymph Node Policy in Intermediate-risk Endometrial Carcinomas | withdrawn | N/A | 0 | Fudan UniversityOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT06099418 | Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. | withdrawn | Phase 2 | 0 | Nykode Therapeutics ASAINDUSTRY | 0 | Sep 20, 2024 | clinicaltrials |
| NCT03150745 | Diagnosis of Cervical Lesions in Women With Unhealthy Looking Cervix | withdrawn | N/A | 0 | Assiut UniversityOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT05033132 | A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer | withdrawn | Phase 2 | 0 | Agenus Inc.INDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT05998941 | A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer | withdrawn | Phase 2 | 0 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05295589 | Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 26, 2023 | clinicaltrials |
| NCT00298064 | Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer | withdrawn | N/A | 0 | University of New MexicoOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05614453 | Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy(ITTACC) | withdrawn | Phase 2 | 0 | Australia New Zealand Gynaecological Oncology GroupOTHER | 0 | Jun 29, 2023 | clinicaltrials |
| NCT05393635 | ITIL-168 in Advanced Solid Tumors(DELTA-2) | withdrawn | Phase 1 | 0 | Instil BioINDUSTRY | 0 | Dec 20, 2022 | clinicaltrials |
| NCT04294836 | Curcumin in Advanced Cervical Cancer | withdrawn | Phase 2 | 0 | Instituto Nacional de Cancerologia, ColumbiaOTHER_GOV | 0 | Dec 7, 2022 | clinicaltrials |
| NCT04368130 | SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care(SIGNAL) | withdrawn | N/A | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT04943627 | Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA) | withdrawn | Phase 3 | 0 | Agenus Inc.INDUSTRY | 2 | Oct 5, 2022 | clinicaltrials |
| NCT03834571 | Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women | withdrawn | Phase 2 | 0 | AIDS Malignancy ConsortiumNETWORK | 2 | Jun 21, 2022 | clinicaltrials |
| NCT04806945 | A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer | withdrawn | Phase 3 | 0 | Shanghai Henlius BiotechINDUSTRY | 1 | May 5, 2022 | clinicaltrials |
| NCT03977311 | MR-Guided High-Intensity Focused Ultrasound in Conjunction With Radiation Therapy for the Treatment of Locally Advanced Cervical Cancer | withdrawn | N/A | 0 | Washington University School of MedicineOTHER | 0 | Apr 1, 2022 | clinicaltrials |
| NCT04611139 | Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers | withdrawn | Phase 1 | 0 | HonorHealth Research InstituteOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT04498520 | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer | withdrawn | Phase 1 | 0 | Pamela MunsterOTHER | 0 | May 18, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT03902379 | Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer | withdrawn | N/A | 0 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT01097239 | Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Imperial College LondonOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT01925378 | A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia | withdrawn | Phase 2 | 0 | The University of Texas Health Science Center, HoustonOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT04411134 | E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 15, 2020 | clinicaltrials |
| NCT01019278 | Proton Beam Radiation Therapy and Cisplatin in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer and Positive Lymph Nodes | withdrawn | Phase 2 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Apr 3, 2020 | clinicaltrials |
| NCT03644459 | Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 | withdrawn | Phase 1 | 0 | Lynkcell Inc.OTHER | 0 | Mar 11, 2020 | clinicaltrials |
| NCT03146039 | Non-Invasive Cervical Cancer Radiotherapy for Stage IB-IVB(NICER) | withdrawn | Phase 2 | 0 | University of California, San DiegoOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT04125225 | What Are the Experiences of Patients With Pseudomyxoma Peritonei? | withdrawn | — | 0 | University of SouthamptonOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT03795272 | Rucaparib Maintenance Therapy in Advanced Cervical Cancer(MaRuC) | withdrawn | Phase 2 | 0 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 1 | Nov 1, 2019 | clinicaltrials |
| NCT00257829 | Improving Tumor Oxygenation in Cervical Cancer | withdrawn | Phase 2 | 0 | University of California, IrvineOTHER | 0 | Dec 3, 2018 | clinicaltrials |
| NCT03220009 | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2018 | clinicaltrials |
| NCT00950261 | Efficacy Study for Postoperative Chemoradiation Using Triweekly Cisplatin in Cervical Cancer Patients | withdrawn | Phase 2 | 0 | Korea Cancer Center HospitalOTHER | 1 | Aug 13, 2018 | clinicaltrials |
| NCT00428194 | Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer | withdrawn | Phase 1 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT03143491 | Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN) | withdrawn | Phase 2 | 0 | DFB Soria, LLCINDUSTRY | 0 | Oct 18, 2017 | clinicaltrials |
| NCT03007771 | Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Oct 6, 2017 | clinicaltrials |
| NCT00600210 | Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer | withdrawn | Phase 2 | 0 | Leo W. Jenkins Cancer CenterOTHER | 1 | Aug 23, 2017 | clinicaltrials |
| NCT00900081 | Cyclooxygenase-2 Expression in Tissue Samples From Patients With a Normal Cervix, Cervical Intraepithelial Neoplasia, or Early Invasive Cervical Cancer | withdrawn | — | 0 | Wake Forest University Health SciencesOTHER | 0 | Aug 1, 2017 | clinicaltrials |
| NCT01176500 | A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00452920 | Docetaxel and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of MiamiOTHER | 1 | Dec 15, 2016 | clinicaltrials |
| NCT02348398 | Phase II Study of Pazopanib and Topotecan in Cervical Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 16, 2016 | clinicaltrials |
| NCT02501278 | A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | May 13, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Aug 19, 2026source: clinicaltrials